Leaving BNY Website

 

You are leaving the BNY Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2024 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
 

To learn more about DRs, please contact DRBrokerSolutions@bnymellon.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE (0.01%), DAX (0.10%), CAC40 (0.05%)

Feb 14 ,2025

  • Synopsis

    • European indices are set to open close to unchanged as the STOXX600 yesterday posted fresh record highs, on Ukraine peace prospects.

    • Asian equities mostly higher Friday. Hang Seng outperforming region with mainland China, Korea and Australia also gaining. Japan weaker while TSMC weighing on Taiwan

    • US equities finished higher in Thursday trading, near best levels, as stocks reversed mostly lower Wednesday session. S&P 500 and Nasdaq now pacing for solid weekly gains.

    • Among central banks updates: Friday sees, in central banks, Czech central bank's publishing latest Monetary Policy Report ay 9:00CET whilst Russia interest rate decision is at 11:30GMT, along with latest medium-term forecast, press conf 13:00,

    • Economic data due today: Spain Jan final CPI, Switzerland Jan PPI, Finland Q4 preliminary GDP, Netherlands Q4 preliminary GDP, Eurozone Q4 GDP (2nd estimate), Greece Jan CPI

    • Earnings reported so far this morning included: Eutelsat Communications, Höegh Autoliners, Huhtamaki, Fabasoft, Unipol Gruppo, Moreld, Rosenbauer International, Safran, Tomra Systems, Norsk Hydro. Moncler yesterday after the close.

    • In the UK: NatWest Group (NWG.LN), SEGRO (SGRO.LN) will report at 7am.

  • Politics/Macro/World News

    • Trump's Ukraine Plans Mean a $3 Trillion Bill for European Allies (BBG )

  • Top company news

    • Earnings/updates

      • SAF.FP (Safran) -- reports FY EPS €7.29 vs consensus €6.89; raises 2025 recurring operating income and FCF guidance

      • UBI.FP (Ubisoft Entertainment) -- reports Q3 IFRS 15 sales €318.1M vs FactSet €303.4M [5 est, €294-313M]

      • HSBA.LN (HSBC Holdings) -- HSBC set to announce $1.5B in annual cost savings as a result of restructuring initiatives - FT (seemingly around 08:00 HKT/19:00 ET/00:00 GMT)

      • MONC.IM (Moncler) -- reports FY net income €639.6M vs FactSet €604.7M [24 est, €586.2-635.0M]

      • NHY.NO (Norsk Hydro) -- reports Q4 adj EPS NOK1.11 vs consensus NOK1.61

      • ENX.FP (Euronext) -- reports Q4 adjusted EPS €1.66 vs consensus €1.64

      • ENX.FP (Euronext) -- Follow-up: Euronext reports FY 2024 results

      • UTDI.GR (United Internet) -- reports prelim FY 2024 EBITDA €1.29B vs FactSet €1.37B

      • MMB.FP (Lagardere) -- reports FY adjusted net income €253M ex-items vs FactSet €204.4M

      • TOM.NO (Tomra Systems) -- reports Q4 EPS €0.18 ex-items vs FactSet €0.13 [7 est, €0.05-0.15]

      • GFC.FP (Gecina) -- reports FY recurrent net income per share €6.42 vs FactSet €6.44 [14 est, €6.29-7.02]

      • GFC.FP (Gecina) -- Follow-up: Gecina reports FY results

      • 1U1.GR (1&1 AG) -- reports preliminary FY EBITDA €590.8M vs prior guidance €686M and FactSet €667.3M [12 est, €633.1-710.3M]

      • WHA.NA (Wereldhave) -- announces agreement to acquire shopping centers Knauf Pommerloch and Knauf Schmiede from Nextensa NV

      • NHH.SM (Minor Hotels Europe & Americas) -- reports Q4 net profit €66.1M vs year-ago €28.5M

      • NVG.PL (The Navigator Co.) -- reports Q4 net income €45.5M vs FactSet €65.7M [4 est, €51-78M]

      • SOLG.LN (SolGold) -- reports Q2 EPS ($0.003) vs year-ago ($0.005)

      • PHOR.RU (PhosAgro) -- board declares operating and financial results for 2024 a success; approves distribution of dividends at a rate of RUB 171 per ordinary share

      • PHOR.RU (PhosAgro) -- reports FY adjusted net income RUB100.4B, (4%) vs year-ago RUB104.1B

      • MOBN.SW (Mobimo Holding) -- reports FY EPS excluding revaluation CHF12.59 vs FactSet CHF12.67 [4 est, CHF12.14-13.55]

    • M&A

      • SAN.SM (Banco Santander) -- reportedly has held talks about potential sale of UK business with NatWest (NWG.LN) -- FT

      • SAN.SM (Banco Santander) -- again says UK business is not for sale -- Reuters, citing spokesperson

      • ALTM (Arcadium Lithium) -- receives all required pre-closing regulatory approvals in connection with acquisition by Rio Tinto

      • KBC.BB (KBC Group) -- exploring acquisitions in Central Europe - Reuters

      • WHA.NA (Wereldhave) -- announces agreement to acquire shopping centers Knauf Pommerloch and Knauf Schmiede from Nextensa NV

    • Healthcare

      • AMGN (Amgen) -- FDA approves second biosimilars of Amgen's Prolia and Xgeva; Samsung Bioepis Xbryk and Opsomyv

      • NOVN.SW (Novartis) -- FDA grants orphan drug designation to ianalumab for ITP

      • BAYN.GR (Bayer AG) -- announces new subgroup data from Phase III ARANOTE trial of NUBEQA in combination with standard ADT in patients with mHSPC

      • GALD.SW (Galderma Group) -- Galderma announces Nemluvio (Nemolizumab) approved in the EU for moderate-to-severe atopic dermatitis and prurigo nodularis

    • Other

      • BNP.FP (BNP Paribas) -- signs agreement with European Investment Bank for €1B in wind energy guarantees

      • GFC.FP (Gecina) -- Gecina's board to propose appointing Philippe Brassac as director

      • KESKOB.FH (Kesko) -- reports Jan sales €935.5M, +1.5% in comparable terms

      • EU wind farms see €1B in guarantees from BNP; US armored EV contract on "hold" in intraday thematic news (13-Feb)

  • Key rating changes

    • Upgrades

      • VAR.NO (Vår Energi) -- to buy from neutral at Goldman Sachs

      • (YAR.NO) Yara International upgraded to neutral from underperform at BNP Paribas Exane

      • (HEIA.NA) Heineken upgraded to outperform from neutral at Oddo

    • Downgrades

      • IVSO.SS (INVISIO) -- to sell from hold at Pareto

      • (DB1.GR) Deutsche Börse downgraded to neutral from outperform at Oddo

    • Initiations

      • P911.GR (Porsche) -- outperform at BNP Paribas Exane

      • KTN.GR (Kontron) -- outperform at Oddo

  • Data

    • Nikkei (0.79%) to 39149.43

    • Hang Seng +2.56% to 22372.24

    • Shanghai Composite +0.26% to 3341.06

    • S&P futures +4.5 vs prior close of 6135.3

    • €-$ (0.0007) or (0.07%) to 1.0460

    • $-¥ (0.28) or (0.18%) to 152.52

    • €-¥ (0.36) or (0.23%) to 159.55

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE